An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)

NCT01332981 · clinicaltrials.gov ↗
COMPLETED
Status
220
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Hoffmann-La Roche